NDAORALCAPSULE, PELLETS
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
8/100
Clinical Trials
51
Data completeness
6/8 — Strong
XALKORI (crizotinib) by Pfizer is cytochrome p450 3a inhibitors [moa]. Approved for non-small cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor and 1 more indications. First approved in 2023.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XALKORI (crizotinib) is an oral kinase inhibitor capsule approved by the FDA on September 7, 2023, developed by Pfizer. It functions as a cytochrome P450 3A inhibitor, blocking specific cellular signaling pathways implicated in cancer growth. The product is indicated for patients with specific molecular alterations, positioning it as a targeted therapy in the oncology treatment landscape.
$0.1BPart D
3.5 years to LOEMechanism of Action
Cytochrome P450 3A Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Worked on XALKORI at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.